Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
1.08
-0.04 (-3.57%)
At close: May 01, 2025, 3:59 PM
1.08
0.02%
After-hours: May 01, 2025, 07:26 PM EDT
-3.57% (1D)
| Bid | 1.08 |
| Market Cap | 37.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.77M |
| EPS (ttm) | -1.26 |
| PE Ratio (ttm) | -0.86 |
| Forward PE | -2.19 |
| Analyst | Buy |
| Ask | 1.3 |
| Volume | 528,282 |
| Avg. Volume (20D) | 409,050 |
| Open | 1.14 |
| Previous Close | 1.12 |
| Day's Range | 1.07 - 1.14 |
| 52-Week Range | 0.81 - 3.02 |
| Beta | 2.88 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company ...
Industry Biotechnology
Sector Healthcare
IPO Date May 25, 2018
Employees 9
Stock Exchange NASDAQ
Ticker Symbol ITRM
Website https://www.iterumtx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ITRM stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 362.96% from the latest price.
Stock Forecasts3 days ago
-15.87%
Iterum Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
6 months ago
+60.68%
Iterum Therapeutics shares are trading higher after the FDA approved the company's new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections.
